TY  - JOUR
AU  - Stratigos, Alexander J
AU  - Sekulic, Aleksandar
AU  - Peris, Ketty
AU  - Bechter, Oliver
AU  - Prey, Sorilla
AU  - Kaatz, Martin
AU  - Lewis, Karl D
AU  - Basset-Seguin, Nicole
AU  - Chang, Anne Lynn S
AU  - Dalle, Stèphane
AU  - Orland, Almudena Fernandez
AU  - Licitra, Lisa
AU  - Robert, Caroline
AU  - Ulrich, Claas
AU  - Hauschild, Axel
AU  - Migden, Michael R
AU  - Dummer, Reinhard
AU  - Li, Siyu
AU  - Yoo, Suk-Young
AU  - Mohan, Kosalai
AU  - Coates, Ebony
AU  - Jankovic, Vladimir
AU  - Fiaschi, Nathalie
AU  - Okoye, Emmanuel
AU  - Bassukas, Ioannis D
AU  - Loquai, Carmen
AU  - De Giorgi, Vincenzo
AU  - Eroglu, Zeynep
AU  - Gutzmer, Ralf
AU  - Ulrich, Jens
AU  - Puig, Susana
AU  - Seebach, Frank
AU  - Thurston, Gavin
AU  - Weinreich, David M
AU  - Yancopoulos, George D
AU  - Lowy, Israel
AU  - Bowler, Timothy
AU  - Fury, Matthew G
PY  - 2021
DO  - 10.1016/S1470-2045(21)00126-1
UR  - http://hdl.handle.net/10668/17800
T2  - The Lancet. Oncology
AB  - Before February, 2021, there was no standard treatment regimen for locally advanced basal cell carcinoma after first-line hedgehog inhibitor (HHI) therapy. Cemiplimab, a PD-1 antibody, is approved for treatment of advanced cutaneous squamous cell...
LA  - en
KW  - Adult
KW  - Aged
KW  - Anilides
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carcinoma, Basal Cell
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Hedgehog Proteins
KW  - Humans
KW  - Immune Checkpoint Inhibitors
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Programmed Cell Death 1 Receptor
KW  - Pyridines
KW  - Skin Neoplasms
TI  - Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
TY  - research article
VL  - 22
ER  -